Year: 2024
Type: other
Abstract: Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.
Source: OncoImmunology
Authors: Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Octavie Demeulenaere, Jannes Govaerts, Lisa Kinget, Saurabh Saraswat, Benoit Beuselinck, Steven De Vleeschouwer, Paul Clement, Frederik De Smet, Rüdiger V. Sorg, Angeliki Datsi, Nathalie Vigneron, Stefan Naulaerts, Abhishek D. Garg
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,913
Funders: KU Leuven, Kom op tegen Kanker
Awards: G3182435129, G713707839
OpenAlex ID: W4403254206